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Drug exposure during pregnancy constitutes a major legal issue and public health 
concern. Drug and metabolite determination in biological matrices from mother and 
newborn is an objective indication of prenatal drug exposure. However, limited data are 
available regarding the interpretation of these analytical results in terms of window of 
detection and degree of exposure. We collected paired maternal hair, meconium, placenta 
and umbilical cord from 727 mother-newborn dyads. We analyzed these specimens by 
liquid chromatography tandem mass spectrometry for the determination of cocaine, 
opioids, methadone and amphetamines, and compared the analytical results from the four 
different matrices. The cases were divided in non-exposure, low and frequent exposure, 
based on maternal hair concentrations and segmental analysis by trimesters. For cocaine, 
64 cases tested positive in hair, 9 in meconium, 6 in placenta and 7 in umbilical cord. In 
the case of opioids, 14 maternal hair cases were positive, 11 meconium and umbilical 
cord and 9 placenta samples. For methadone, 11 cases were positive in hair, 9 in 
meconium and 6 in placenta and umbilical cord. For amphetamines, 18 cases were 
positive according to maternal hair, but all meconium, placenta and umbilical cord tested 
negative. Maternal hair was the most sensitive specimen to detect drug exposure during 
pregnancy. Meconium, placenta and umbilical cord tested positive if hair concentrations 
showed frequent drug use during the whole pregnancy, especially during the third 
trimester. Meconium, placenta and umbilical cord also tested positive for morphine and 
metabolites, if this drug was administered during labor and delivery.  
 

























The consumption of drugs of abuse during pregnancy not only constitutes a major public 
health issue, but also an important legal concern. Prenatal exposure to drugs of abuse has 
been associated with deleterious short- and long-term effects in the exposed children1, 2. 
The type of harm depends on the trimester of the pregnancy. Heavy drug use during the 
first trimester may result in abortions and malformations (teratogenic effects)3, 4. In the 
second and third trimesters, the main harmful effects are related to fetal growth and 
maturation. One of the most deleterious short-term effects is the neonatal abstinence 
syndrome (NAS)5, and among the long-term effects, problems in neurodevelopment 
(memory, attention, learning skills)6, 7. Gestational exposure to licit and illicit drugs is 
considered the single largest preventable cause of in utero developmental compromise of 
infants in the USA8. Early diagnosis and treatment achieves the best outcomes. Besides 
the direct harm on the exposed children, the presence of drug use disorders in parents 
increases the risk of child maltreatment by threefold or more9, 10.  
In the USA and Europe, drug toxicology screening programs for pregnant women 
and newborns continue to expand. However, evidence-based guidelines, policies for drug 
screening/confirmation and referrals in this population are missing. The American 
Congress of Obstetrics and Gynecology (ACOG) recommends universal drug screening 
vs. risk-based screening, because the later tends to unfairly target low-income women11. 
The treatment for these women and their detection is complicated because of the 
involvement of the child welfare and legal systems by wide-ranging country statues, 
some of which are clinical treatment oriented and some of which are punishment 
oriented8. In the USA, the states of Alabama, South Carolina, and Tennessee have moved 
to criminalize drug use during pregnancy. In Spain, it is under discussion12. 
Although maternal interview is the most commonly employed method to detect 
drug exposure during pregnancy, it is often unreliable due to the under-reporting 13. The 
determination of drugs and metabolites in biological specimens from the mother (urine, 
blood/plasma, oral fluid, sweat), from the newborn (urine, meconium and hair) and from 
the fetal-maternal unit (amniotic fluid, placenta and umbilical cord) offers an objective 
evidence of this exposure. Previously published reviews discussed the advantages and 
disadvantages of some of these matrices14-19; however, data about the alternative matrices 
placenta and umbilical cord are scarce18. Also the interpretation of the analytical results 
of the neonatal biological samples in terms of window of detection and degree of 
exposure is still not well established. 
Maternal hair analysis shows the longest window of detection. Taking into 
account that hair grows at an accepted rate of 1 cm/month20, segmental hair analysis can 
describe the drug exposure throughout the whole pregnancy. Other biological specimens 
from the mother, such as blood, oral fluid and urine, show a much shorter window of 
detection (blood and oral fluid hours, and urine days). Among the different specimens 
from the newborn, meconium, the first stool of an infant, is nowadays considered the 
“gold standard” to reflect drug exposure during the third trimester18. However, its 
expulsion may take up to 5 days after delivery, or it could be passed in utero, making this 
matrix unavailable for drug testing. Placenta and umbilical cord offer the advantages of 
being available at birth and in adequate amount for analysis. However, data about drug 
and metabolite concentrations and window of detection is limited18, 21.    
We collected and analyzed paired biological samples from 727 mother and 
newborn dyads, including maternal hair, meconium, placenta and umbilical cord, to study 
drug exposure to cocaine, opioids, methadone and amphetamines during pregnancy. 
Maternal hair was employed as reference to establish the timing and the degree of 
exposure to the drugs of interest. These biological samples (maternal hair, meconium, 
placenta and umbilical cord) were compared in terms of windows of detection, analyte 
and metabolite profile and predominant analytes, and concentrations.  
  




The participants were pregnant women who delivered at the University Hospitals of 
Santiago de Compostela and Vigo, Spain, from January 2012 to December 2015. The 
participants were informed about the study both in writing and orally before the delivery, 
and they gave written consent. The subjects were not paid for their participation. The 
study was approved by the Ethics Committee of the University of Santiago de 
Compostela, Spain. Eight hundred fifty eight pregnant women agreed to participate in the 
study. All biological specimens (maternal hair, meconium, placenta and umbilical cord) 
were collected in 727 cases. 
 
Specimen Collection and Storage 
 
The entire term placenta and umbilical cord specimens were collected at delivery in a 
polypropylene container and stored at -20°C until analysis. Meconium specimens were 
collected from newborn diapers up to 3 days after delivery in polypropylene containers 
and also stored at -20°C until analysis. Maternal hair specimens (a lock of about 100 
hairs) were collected after the delivery from the vertex posterior region, as close as 
possible from the scalp and tied up at the root. These specimens were stored protected 




All maternal hair specimens and meconium specimens were analyzed for cocaine, 
opiates, methadone and amphetamines. Umbilical cord and placenta were analyzed if 
either maternal hair or meconium specimens tested positive for any drug or metabolite. 
Maternal hair, whenever possible based on the length and amount of hair 
available, was segmented by trimesters. Each lock of hair was measured, and divided into 
3 segments corresponding to the 3 trimesters: segment 1 (2 cm long) from 0 (root) to 2 
cm for the 3rd trimester; segment 2 (3 cm long) from 3 to 5 cm for the 2nd trimester; and 
segment 3 (3 cm long) from 6 to 8 cm for the 1st trimester. If the amount of hair was not 
enough for segmentation, only 1 segment up to 8 cm long was analyzed (whole 
pregnancy). 
Maternal hair22, meconium21 and placenta and umbilical cord23 were analyzed by 
previously published liquid chromatography tandem mass spectrometry (LC-MSMS) 
methods. Briefly, hair specimens were analyzed for 35 licit and illicit drugs in 50 mg of 
hair, including cocaine, opioids, methadone and amphetamines. Hair decontamination 
was performed with dichloromethane and incubation in 2 mL acetonitrile overnight at 
50°C. The extraction procedure consisted in a liquid-liquid extraction 
(hexane:ethylacetate, 55:45 v/v, at pH 9), followed by reversed-phase solid phase 
extraction (Strata-X cartridges, Phenomenex, Torrance, CA). Reversed-phase 
chromatographic separation was performed in an Atlantis T3 2.1x100 mm 3 µm column 
(Waters, Milford, MA), with acetonitrile and ammonium formate pH 3 as mobile phase 
and a 32 minute of total run time. The method was linear from 0.5-100 to 2,000-20,000 
pg/mg, depending on the compound, and the limit of detection (LOD) was 0.5-100 
pg/mg. 
Placenta and umbilical cord were analyzed for the determination of opioids 
(morphine, morphine-3-glucuronide, morphine-6-glucuronide, codeine, 6-acetilmorphine 
(6 AM)), amphetamines (amphetamine, methamphetamine, 3,4-
methylenedioxyamphetamine(MDA), 3,4-methylenedioxymethamphetamine 
(MDMA)), cocaine (cocaine, benzoylecgonine (BE), ecgonine methyl ester (EME), 
hydroxy-benzoylecgonine (OH-BE)) and methadone (methadone, and 2-ethylidene-1,5-
dimethyl-3,3-diphenylpyrrolidine (EDDP)). One gram (±0.02 g) of placenta or umbilical 
cord was homogenized in 5 mL of water with the Ultra-Turrax T8 dispenser (IKA, 
Staufen, Germany). After the addition of 50 µL of 10% formic acid and centrifugation, 
the supernatants were submitted to cation exchange solid phase extraction (OASIS MCX 
cartridges, Waters). Chromatographic separation was performed in an Atlantis T3 2.1 x 
100 mm 3 µm column (Waters), acetonitrile and 0.1% formic acid as the mobile phase, 
and 18 minutes of total run time. The linearity ranged from 1-2.5 ng/g to 100-500 ng/g, 
and the LOD was 0.5-2.5 ng/g, depending on the compound. 
Meconium was analyzed for the same drugs and metabolites as placenta and 
umbilical cord. In this case, 0.5±0.01 g of meconium was pretreated with 2 mL of 
methanol + 0.01% formic acid, and mixed in a rotor for 30 minutes. After centrifugation, 
the supernatant was evaporated to dryness and reconstituted in 200 µL methanol and 2 
mL of 0.1% formic acid. This solution was submitted to cation exchange solid phase 
extraction (OASIS MCX cartridges, Waters). Chromatographic separation was performed 
in an Atlantis T3 2.1 x 100 mm 3 µm column (Waters), acetonitrile and formic acid 0.1% 
as mobile phase, and 18 minutes of the total run time. The LOD was 0.5-2.5 ng/g, 
depending on the compound, and the linearity was from 5 to 500 ng/g. Supplemental 
Table 1 summarizes the LOD, LOQ and cutoffs for each analyte for each specimen. 
 
Comparison of Hair, Meconium, Placenta and Umbilical Cord 
 
To compare the different matrices, we considered maternal hair as the reference matrix. 
We classified the degree of exposure based on hair concentrations in “frequent 
exposure”, “low exposure” and “non-exposure”. For “frequent exposure” we used the 
cutoff values recommended by the Society of Hair Testing (SoHT) for opioids (morphine 
or 6-AM at 200 pg/mg), for cocaine (cocaine at 500 pg/mg and BE at 50 pg/mg), and for 
amphetamines (amphetamine, methamphetamine, MDA or MDMA at 200 pg/mg). In the 
case of methadone we established the cutoff at 200 pg/mg, similar to opioids. For “low 
exposure” we employed the method’s LOQ for the compounds of interest (20 pg/mg) up 
to SoHT cutoff values. “Non-exposure” specimens were the cases where drugs were 
negative. For meconium, placenta and umbilical cord, the specimens were considered 






Sixty-two cases were positive for cocaine in hair (8.7% of total samples). Thirty-four 
specimens out of 62 could be segmented by trimesters, corresponding to the first, second 
and third trimester, and in 28 cases only one segment 8 cm long, reflecting the whole 
pregnancy, was analyzed. The concentrations in the segmented specimens (n=34 cases) 
were cocaine 20-24,275 pg/mg (n=76 segments), BE 20-15,355 pg/mg (n=74 segments) 
and cocaethylene 20-281 pg/mg (n=11 segments). Eight cases showed at least one of the 
3 segments with concentrations above the SoHT cocaine cutoff; 4 cases showed all the 
three segments above SoHT cutoff, 3 cases showed only the third segment (first 
trimester) above the cutoff, and one case the second and the third segments (first and 
second trimester). With regard to the one segment specimens, the concentrations were 
cocaine 31-22,390 pg/mg (n = 29 samples), BE 34-23,730 pg/mg (n = 29 samples) and 
cocaethylene 20-361.5 pg/mg (n = 9 samples). Thirteen samples showed concentrations 
above the SoHT cocaine cutoff. 
Nine meconium specimens were positive for cocaine and metabolites (1.2% of 
total samples). OH-BE was detected in all samples (n=9) at concentrations 10-321 ng/g. 
EME (4-517 ng/g), BE (2-428 ng/g) and cocaine (5-111 ng/g) were detected in 8 samples, 
and cocaethylene (3-95.3 ng/g) in 3 samples. Placenta and umbilical cord were analyzed 
for cocaine and metabolites if hair (n=62) or meconium (n=9) were positive. Six placenta 
specimens were positive for cocaine metabolites (0.96% of total samples). EME was 
positive in 6 samples (1-7 ng/g), BE in 5 cases (1-24 ng/g) and OH-BE in one at 1 ng/g. 
All placenta samples were negative for cocaine and cocaethylene. Seven umbilical cord 
samples were positive for cocaine and metabolites. EME was positive in 6 samples (1-5.5 
ng/g), BE in 6 samples (1-39.3 ng/g) and cocaine in 2 cases (2.4-6.2 ng/g). All umbilical 
cord samples were negative for OH-BE and cocaethylene. These results are summarized 
in Table 1. 
Segmental analysis could be performed in 34 hair samples. If all hair segments 
were above the SoHT cutoff (n=4 cases), which reflected “frequent exposure” throughout 
the whole pregnancy, the 3 matrices, meconium, placenta and umbilical cord, were 
positive for cocaine and metabolites. If one or two hair segments, corresponding with the 
first and/or second trimesters, were above the SoHT cutoff (n=4), meconium, placenta 
and umbilical cord tested negative for cocaine and metabolites. In all other cases, if hair 
concentrations were positive but below SoHT cutoff or negative, all meconium, placenta 
and umbilical cord were negative (Figure 1). 
Twenty-eight hair samples could not be divided in segments, and one 8 cm long 
segment was analyzed. Thirteen of those cases showed concentrations above the SoHT 
cutoff. Among these cases, 5 meconium samples were positive for cocaine and 
metabolites, 3 umbilical cord and 2 placenta samples. If the 8 cm long segment 
concentrations were below SoHT or negative, all meconium, placenta and umbilical cord 
were negative (Figure 1). 
Comparing meconium, placenta and umbilical cord concentrations and metabolite 
profile, meconium was the matrix that showed the highest concentrations followed by 
umbilical cord and placenta. The predominant metabolite in meconium was OH-BE and 




Fourteen cases were positive for opioids (morphine, codeine, 6-AM) in hair (1.9% of 
total cases). Nine cases could be analyzed in 3 segments, while in 5 cases only one 8 cm 
long segment could be analyzed. The concentration ranges in the segmented cases were 
morphine 30-624 pg/mg (n=10 segments), codeine 20-59 pg/mg (n=6 segments), and 6-
AM 20-1,258 pg/mg (n=10 segments). Six cases showed at least one segment above the 
SoHT opioids cutoff; in one case all three segments were above the cutoff, and in 5 cases 
the second segment that corresponded with the second trimester was above the cutoff. 
The 8 cm long hair segments showed morphine at 20-284.4 pg/mg (n=4), codeine 20 
pg/mg (n=3) and 6-AM 28.8-155.5 pg/mg (n=4). Two of these samples were above the 
SoHT cutoff. 
Eleven meconium samples were positive for opioids. Morphine was detected in 
all cases (5-109.2 ng/g), morphine-3-glucuronide in 4 cases (5.4-53.2 ng/g), and 
morphine-6-glucuronide in 2 cases (1.6-5 ng/g). 6-AM and codeine were not detected in 
any sample. Nine placenta samples tested positive for opioids. Morphine and morphine-
3-glucuronide were positive in all cases (1-4.6 ng/g and 10.2-40 ng/g, respectively) and 
morphine-6-glucuronide in 3 cases (1.3-8.1 ng/g). Codeine and 6-AM were not detected 
in any sample. Eleven umbilical cord samples were positive for opioids. Morphine and 
morphine-3-glucuronide were detected in all the specimens (morphine 1-18.9 ng/g, 
morphine-3-glucuronide 8.8-95.8 ng/g) and morphine-6-glucuronide in 8 cases (2-11.1 
ng/g). Codeine and 6-AM were not detected in any of the umbilical cord samples. These 
results are summarized in Table 2. 
Nine hair samples were analyzed in 3 segments corresponding to the different 
trimesters during pregnancy. One case showed hair concentrations above the SoHT 
opioids cutoff for all the segments, and meconium, placenta and umbilical cord were 
positive. The predominant analyte in meconium was morphine, and in placenta and 
umbilical cord was morphine-3-glucuronide. In five cases, only the second segment, 
reflecting the second trimester, was above the SoHT cutoff, and all the 3 matrices were 
negative. Among the 8 cm long hair segments, 2 cases showed concentrations above the 
SoHT cutoff, and meconium, placenta and umbilical cord were negative (Figure 2). 
In 10 cases, although maternal hair opioid analysis was negative, meconium, 
placenta and/or umbilical cord tested positive for morphine and/or its metabolites, 
morphine 3- and 6-glucuronide. In all these cases morphine was administered to the 




Eleven cases out of 727 were positive for methadone in hair (1.5% of total). Six cases 
could be submitted for segmental analysis, and 5 were analyzed in one segment of 8 cm. 
The segmented samples showed methadone from 42.7-14,776.1 pg/mg (n=18 segments), 
and the one segment samples showed methadone in the range 55.1-3,838 pg/mg (n=5). 
Nine meconium samples were positive for methadone exposure. EDDP was 
detected in all cases with concentrations from 14.6 to 6,049 ng/g, and methadone in 7 
samples with concentrations from 244.5 to 3,926 pg/mg. Placenta and umbilical cord 
were positive in 6 cases, being methadone and EDDP detected in all samples. For 
placenta, methadone concentrations ranged from 42.1 to 366.3 ng/g and EDDP from 5.1 
to 1,975 ng/g. In the case of umbilical cord, methadone concentrations were 4.3-763 ng/g 
and EDDP 1-143.2 ng/g. Meconium showed higher concentrations compared to placenta 
and umbilical cord. The predominant analyte in meconium was the metabolite EDDP, but 
in most placenta and in all umbilical cord samples it was methadone. These results are 
summarized in Table 3.  
Meconium, placenta and umbilical cord tested positive if all the 3 hair segments 
throughout pregnancy were positive for methadone, regardless if these concentrations 
were above or below the 200 pg/mg cutoff (all 3 hair segments concentrations ≥ 42.7 
pg/mg). In the case of one segment samples, if methadone concentrations were above the 
“200 pg/mg” cutoff (n=3), all meconium samples were positive, 2 placenta and 2 
umbilical cord samples. If methadone hair concentrations were below 200 pg/mg (n=2), 




In the case of the amphetamines, 18 cases were positive in hair (2.5% of total cases). Ten 
could be analyzed in segments, and 8 cases were analyzed as one 8 cm segment. In the 
segmented samples, the analytes detected were amphetamine (33.4-1,204 pg/mg, n=9 
segments), methamphetamine (24.2-130 pg/mg, n=5 segments), MDA (65.6-189 pg/mg, 
n=3 segments) and MDMA (39.4-191.3 pg/mg, n=6 segments). The concentrations in the 
one segment samples were amphetamine (53.2-1,899 pg/mg, n=6), methamphetamine 
(37.8-137.4 pg/mg, n=4), MDA (78.3-118.4, n=2) and MDMA (38-209.8 pg/mg, n=5).  
Among the segmented cases, only in one case one segment corresponding with 
the first trimester of pregnancy showed amphetamine concentrations above SoHT cutoff. 
All the meconium, placenta and umbilical cord samples tested negative. Although in the 
case of one segment hair samples, 3 cases showed amphetamine concentrations above the 
established cutoff and one MDMA case was above the cutoff, all meconium, placenta and 




We analyzed biological matrices from 727 mother-newborn dyads for the determination 
of cocaine, opioids, methadone and amphetamines collected from 2012 to 2015. The goal 
of the study was to compare maternal hair, meconium, placenta and umbilical cord in 
terms of windows of detection, predominant analytes and metabolites detected, and 
concentrations. Maternal hair was considered the reference matrix to establish the drugs 
consumed, timing and degree of exposure (non-exposure, low or sporadic and frequent), 
and all the cases were analyzed for the drugs of interest. Also meconium was analyzed in 
all cases because this is the current “gold standard” matrix to detect in utero drug 
exposure. We explored placenta and umbilical cord as an alternative to detect drug 
exposure during pregnancy. Placenta and umbilical cord were analyzed if either maternal 
hair or meconium specimens were positive to any drug (n=124). The authors performed a 
pilot study in 2011 with 175 cases, which results were previously published21. In that 
study, 21 cases were positive for cocaine (12%), 2 for opioids (1.1%), 5 for methadone 
(2.9%) and one for amphetamines. Due to the limited number of positive specimens, the 
study was underpowered. The present work with a larger cohort (727 mother-newborn 
dyads) was conducted to establish valid observations.   
The analytical determination of drugs and/or metabolites in different biological 
matrices from the mother and the newborn offers an objective identification of drug 
exposure during pregnancy. The interpretation of the analytical results in the different 
biological matrices tries to determine when the exposure happened during the pregnancy 
(first, second or third trimester), for how long (sporadic or frequent) and what amount of 
drugs were consumed by the mother. Maternal hair shows the longest window of 
detection and it has been used to monitor drug exposure during pregnancy19. Maternal 
hair is considered the most sensitive specimens to detect drug consumption during this 
period18, 24. In the present study, also maternal hair was the most sensitive biological 
sample to detect drug use or abuse during the whole pregnancy. In addition, as we 
showed in this study, hair was useful to differentiate between mother use and drugs 
administered during labor and delivery (opioids hair test negative vs. opioids positive in 
meconium, placenta and umbilical cord). Despite its usefulness, maternal hair monitoring 
is not a direct maker of in utero drug exposure, and in some countries, such as the USA, 
still is required a newborn specimen as evidence of child abuse25.  
Meconium has become the “gold standard” for drug exposure detection in 
newborns. Because its formation starts around the 12th week of gestation and it 
accumulates until birth, it was considered that it reflected drug exposure during the 
second and third trimester14, 15. However, it is known that its formation increases during 
the last trimester (week 28 – 40), and about 75% of meconium is produced during the last 
8 weeks of pregnancy26. Because of this, meconium results may reflect just the last 2-3 
months of pregnancy27. Previous studies also showed that not just the timing but also the 
frequency of drug exposure was critical to be able detect drugs in meconium. A frequent 
and chronic exposure is necessary to produce meconium positive results 21, 28. Our results 
are in agreement with these previous studies. Meconium only was positive if a frequent 
drug abuse was documented by hair analysis during the whole pregnancy for cocaine, 
opioids and methadone, especially during the third trimester.  
Umbilical cord tissue is an emerging specimen of considerable interest. Its 
collection is easy and noninvasive, and compared to meconium it offers the advantages of 
abundant amount of specimen and readily available at delivery. However, few studies 
about umbilical cord fully describing this matrix to detect in utero drug exposure 
(predominant analytes and metabolites, concentrations and windows of detection) are 
available18. Recently, Marin et al29 developed a screening method of 57 drugs in 
umbilical cord tissue by liquid-chromatography time-of-flight (TOF) mass spectrometry, 
and compared paired umbilical cord and meconium samples (n=7). Conflicting results 
were obtained, and only 2 cases showed meconium-umbilical cord good matching results. 
Jones et al30 developed a method for the detection of heroin exposure in umbilical cord. 
The identification of heroin exposed newborns improved due to the monitoring of 
meconin, a metabolite of the illicit heroin contaminant noscapine. No comparison with 
other specimens was performed. Our present data show that umbilical cord tissue could 
be an alternative to meconium; however, more sensitive analytical techniques are 
required due to the lower concentrations detected in this biological sample. It is important 
to highlight the differences between the most predominant analyte and/or metabolites 
between these matrices. In the case of cocaine, the most prevalent and/or abundant 
compound was OH-BE in meconium and BE in umbilical cord. With regard to the 
opioids, our results showed that it is critical to monitor morphine-3-glucuronide in the 
case of umbilical cord. This incorporation of glucuronides in umbilical cord samples has 
been indicated previously 21, 31. Methadone was the predominant metabolite in umbilical 
cord, while the EDDP was the target compound in meconium32. In the present study, 
meconium and umbilical cord positive results agreement was 60% for cocaine, 100% for 
opioids and 70% for methadone.  
Several studies have been published about placenta as alternative matrix to detect 
in utero drug exposure21, 33, 34. Falcon et al34 compared maternal hair with placenta and 
fetal remains from abortions at the 12th week of gestation. In that study hair was more 
sensitive than placenta to detect cocaine (20% placenta positive) and opiates (none 
placenta positive) exposure. Previous comparisons between meconium, umbilical cord 
tissue and placenta showed that placenta performed similar to umbilical cord and both 
matrices were less sensitive than meconium for cocaine and opiates21, 32, 33. In the present 
study a better agreement among meconium and placenta results were observed. 
Meconium and placenta positive results agreement was 60% for cocaine, 81.8% for 
opioids, and 70% methadone. As reported before21, 33, we found that placenta 
concentrations were 5 to 10-fold lower than meconium concentrations, and the 
predominant compound were different in placenta compared to meconium (Tables 1-3), 
suggesting a higher accumulation happens in meconium. However, this behavior may be 
the opposite for other compounds such as caffeine and theobromine35 and 
benzodiazepines29, 36.  
The anatomical/physiological differences of these matrices and the physico-
chemical properties of the drugs and metabolites may influence the different 
incorporation of drugs and metabolites in meconium, umbilical cord and placenta. We 
observed a tendency of higher accumulation of more polar compounds in umbilical 
cord/placenta and more apolar compounds in meconium for some drug groups, such as 
opioids. All these information should bear in mind in the development of analytical 
methods in the different matrices to select the appropriate target compounds and 
concentration range. 
Cocaethylene is a specific metabolite that is formed if cocaine and ethanol are 
consumed simultaneously. Meconium samples were positive for cocaethylene in 3 cases, 
where the hair concentration was above 131 pg/mg in the third trimester (segment 1) or 
above 180 pg/mg during the whole pregnancy (8 cm segment). In these cases, placenta 
and umbilical cord were negative for this metabolite. Other alcohol biomarkers, such as 
fatty acid ethyl esters and ethyl glucuronide and sulfate, have being detected in 
meconium37; however, umbilical cord and placenta data are scarce38, 39. Unfortunately, 
other alcohol biomarkers were not investigated in the present study. 
Meconium, umbilical cord and placenta reflected drug exposure during 
pregnancy, but also it is important to highlight that they may reflect drugs administered 
during labor and delivery. This fact has been reported previously in meconium and 
umbilical cord29, 40, but there is no data about placenta. In the present study we detected 
10 cases that tested positive for morphine and metabolites in these three alternative 
matrices, due to the administration of morphine to the mother during labor and delivery. 
The analysis of maternal hair samples excluded opioids use during pregnancy. Although 
meconium also has been reported positive if drugs were administered to the newborn40, 
the employment of umbilical cord and placenta would exclude these cases. 
A limitation of this study could be that not all placenta and umbilical cord 
samples were analyzed, and therefore a completely comparison with hair and meconium 
could not be performed. In order to optimize laboratory resources and to be able to 
analyze the highest number of cases as possible to obtain significant results (n=727), 
placenta and umbilical cord samples were analyzed if either hair or meconium were 
positive to any of the investigated drugs or metabolites (n=124). Following the present 
approach, we could have missed cases where hair and meconium were negative, and 
placenta and/or umbilical cord were positive, but based on previous studies21,28, this 
number is probably marginal and it would not affect the obtained results. Another 
observation of the present study was that higher concentrations were found in meconium 
compared to placenta and umbilical cord. Even though the employed placenta and 
umbilical cord cutoffs (1-2.5 ng/g) were lower than meconium cutoffs (5 ng/g), the 
development of more sensitive analytical methods in placenta and umbilical cord could 





We presented the most comprehensive study to date comparing maternal hair, meconium, 
placenta and umbilical cord for the detection of drug exposure during pregnancy. 
Maternal hair is the most sensitive matrix to detect cocaine, opioids, methadone and 
amphetamines use and/or abuse during the three trimesters. Meconium, placenta and 
umbilical cord reflect drug exposure if the mother drug use was frequent and during the 
whole pregnancy, specially the third trimester. Attention should be paid to the drugs 
administered during labor and delivery, because meconium, placenta and umbilical cord 
may test positive. 
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Table 1. Quantitative results for cocaine and its metabolites benzoylecgonine (BE), 
hydroxy-BE (OH-BE), ecgonine methyl esther (EME) and cocaethylene (CE) in 
meconium (n=9 total positive cases), placenta (n=6 total positive cases) and umbilical 
cord (n=7 total positive cases). 
 
Matrix Cocaine (ng/g) BE  (ng/g) OH-BE (ng/g) EME (ng/g) CE (ng/g) 
Meconium 5 -111  (n=6) 
2 – 428 
(n=9) 
10 – 321 
(n=10) 
4 – 517 
(n=9) 
3 – 95.3 
(n=3) 
Placenta 0 1 – 24 (n=6) 
1 
(n=1) 






1 – 39.3 
(n=6) 0 
1 – 5.5 
(n=6) 0 
 
Table 2. Quantitative results for morphine, morphine-3-glucuronide (M-3-Gluc) and 
morphine-6-glucuronide (M-6-Gluc) in meconium (n=11 total positive cases), placenta 
(n=9 total positive cases) and umbilical cord (n=11 total positive cases). 6-
monoacetylmorphine (6-AM) and codeine were not detected in any specimen.  
 
Matrix Morphine (ng/g) M-3-Gluc  (ng/g) M-6-Gluc (ng/g) 
Meconium 5 – 109.2 (n=11) 
5.4 – 53.2  
(n=4) 
1.6 – 5 
(n=2) 
Placenta 1 – 4.6 (n=9) 
10.2 – 40 
(n=9) 




1 -18.9  
(n=11) 
8.8 - 95.8 
(n=11) 
2 -11.1  
(n=8) 
 
Table 3. Quantitative results for methadone and its metabolite 2-ethylidene-1,5-dimethyl-
3,3-diphenylpyrrolidine (EDDP) in meconium (n=9 total positive cases), placenta (n=6 
total positive cases) and umbilical cord (n=6 total positive cases). 
 
Matrix Methadone (ng/g) EDDP  (ng/g) 
Meconium 244.5 – 3,926 (n=7) 14.6 – 6,049 (n=9) 
Placenta 42.1 – 366.3 (n=6) 5.1 – 1,975 (n=6) 
Umbilical 






    
Figure legends 
 
Figure 1. Cocaine positive cases in hair segmented by trimesters (n=34) (A) and in hair 
one 8 cm long segment (n=28) (B) above and below the Society of Hair Testing (SoHT) 
cutoff compared to cocaine positive cases in meconium (n=9), placenta (n=6) and 
umbilical cord (n=7). 
 
Figure 2. Opioids positive (above and below SoHT cutoff) and negative (below method’s 
limit of quantification) cases in hair segmented by trimesters (n=9 positive, n=9 negative) 
(A) and in hair one 8cm long segment (n=5 positive, n=1 negative) (B) compared to 
opioid positive cases in meconium (n=11), placenta (n=9) and umbilical cord (n=11). 
 
Figure 3. Methadone positive (above and below 200 pg/mg cutoff) cases in hair 
segmented by trimesters (n=6) (A) and in hair one 8 cm long segment (n=5) (B) 

































































LOD LOQ SoHT 
cutoff 
LOD LOQ LOD LOQ LOD LOQ 
Cocaine 2 20 500 0.5 5 0.5 1 0.5 1 
BE 10 20 50 0.5 5 0.5 1 0.5 1 
CE 10 20 - 0.5 5 0.5 1 0.5 1 
OH-BE - - - 2.5 5 0.75 1 0.5 1 
EME - - - 0.5 5 0.5 1 0.75 2.5 
Morphine 5 20 200 2.5 5 0.75 1 0.75 1 
Codeine 2 20 - 2.5 5 1 2.5 0.75 1 
6-AM 2 20 200 2.5 5 0.75 1 0.75 1 
M-3-G - - - 2.5 5 1 2.5 2.5 5 
M-6-G - - - 2.5 5 1 2.5 2.5 5 
Methadone 2 20 - 0.5 5 0.5 1 0.5 1 
EDDP - - - 0.5 5 0.5 1 0.5 1 
A 2 20 200 2.5 5 0.75 1 2.5 5 
MA 2 20 200 2.5 5 0.75 1 0.5 1 
MDA 2 20 200 0.5 5 0.5 1 1 2.5 

































































































Figure 3.  
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